Skip to main content
Premium Trial:

Request an Annual Quote

ABI, Breaking Silence, Says It Is Working on Next-Generation Sequencing Technologies

NEW YORK, Sept. 29 (GenomeWeb News) - Applied Biosystems President Cathy Burzik acknowledged yesterday that the firm is working on next-generation DNA sequencing technologies, but said the company is not ready to provide details.

 

ABI has "a number of approaches under development," she said during a Q&A session following her presentation at the UBS Global Life Sciences Conference, held here this week. Burzik said a "cluster approach" was one possibility for development, but she declined to provide further details, saying that the firm is working on patent filings.

 

Company officials have been asked frequently over the past year about whether ABI is developing any technologies that would eventually replace its capillary electrophoresis sequencing instruments. Industry insiders also are keen to learn whether ABI plans to partner with or acquire one of the many firms developing alternative sequencing technologies. Up until now, ABI had declined to answer those questions.

 

At the JP Morgan Healthcare Conference in San Franciscoin April, Burzik said that the firm had identified 35 companies that were developing the alternative approaches, such as single-molecule sequencing and DNA clustering efforts. 454 Life Sciences, Agencourt Bioscience, Solexa, and Helicos BioSciences have the most advanced of these new technologies, with instruments either placed or soon to be placed at major research institutions.

 

However, these newer technologies are still several years away from delivering on the promise of the $1,000 genome. Lee Hood, president of the Institute for Systems Biology, recently told GenomeWeb News, "My guess is that within 10 years there'll be new nanotechnology approaches that will ... make the human genome well under $1,000."

 

Burzik reiterated on Wednesday ABI's belief that the newer technologies are not going to make an impact over the next couple of years, and the firm does not see an end to the dominance of capillary electrophoresis in the DNA sequencing market. "We're very committed to sequencing," she said, noting that the firm has more than 12,000 capillary electrophoresis instruments installed worldwide.

 

A complete version of this article appears in the current issue of BioCommerce Week, a GenomeWeb News sister publication.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.